WO2020000453A1 - 一种靶向人 INDO 基因的新型 RNAi 干扰片段、 RNAi 载体及其制备方法和其应用 - Google Patents

一种靶向人 INDO 基因的新型 RNAi 干扰片段、 RNAi 载体及其制备方法和其应用 Download PDF

Info

Publication number
WO2020000453A1
WO2020000453A1 PCT/CN2018/093863 CN2018093863W WO2020000453A1 WO 2020000453 A1 WO2020000453 A1 WO 2020000453A1 CN 2018093863 W CN2018093863 W CN 2018093863W WO 2020000453 A1 WO2020000453 A1 WO 2020000453A1
Authority
WO
WIPO (PCT)
Prior art keywords
rnai interference
gene
vector
indo
novel
Prior art date
Application number
PCT/CN2018/093863
Other languages
English (en)
French (fr)
Inventor
毛吉炎
Original Assignee
深圳市博奥康生物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 深圳市博奥康生物科技有限公司 filed Critical 深圳市博奥康生物科技有限公司
Priority to PCT/CN2018/093863 priority Critical patent/WO2020000453A1/zh
Publication of WO2020000453A1 publication Critical patent/WO2020000453A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease

Definitions

  • the invention relates to the field of biotechnology, in particular to a novel RNAi interference fragment targeting a human INDO gene, an RNAi vector, a preparation method and an application thereof.
  • the immune response is affected and regulated by a variety of factors, thereby maintaining a stable body environment.
  • Indo expressed by antigen-presenting cells such as macrophages and dendritic cells eliminates tryptophan in the local microenvironment, induces apoptosis of T lymphocytes, and suppresses the clonal proliferation of T cells through the role of regulatory T cells.
  • For the regulation of cellular immunity it plays an important role in maintaining the normal pregnancy of the body and the occurrence and development of diseases such as autoimmune diseases, organ transplant rejection, and tumors.
  • the activity of INDO may be a new way to find drugs for the prevention and treatment of immune-related diseases, and solid research is required before it can be put into practical use.
  • solid research is required before it can be put into practical use.
  • due to the poor specificity of this technology the potential risk of off-target is greater, which has hindered the progress of related research.
  • RNA-targeted CRISPR enzyme Cas13a
  • CRISPR / Cas9 which cuts DNA
  • CRISPR / Cas13a can be used to cut specific RNA sequences in bacterial cells.
  • the present invention provides a novel RNAi interference fragment that targets the human INDO gene, an RNAi vector, a preparation method and application thereof.
  • the main purpose is to improve the RNAi specificity of the INDO gene, reduce or eliminate off-target effects, and promote INDO. Study of gene function.
  • the present invention mainly provides the following technical solutions:
  • RNAi interference fragment used to interfere with the human INDO gene, the sequence of which is as SEQ ID NO.1.
  • RNAi interference vector is used to interfere with the human INDO gene.
  • the novel RNAi interference vector clone carries a novel RNAi interference fragment, and the sequence of the novel RNAi interference fragment is as SEQ ID NO.1.
  • novel RNAi interference vector includes a pRNAT-LwCas13a-Neo vector, and the pRNAT-LwCas13a-Neo vector is connected to the novel RNAi interference fragment.
  • a method for preparing a novel RNAi interference vector includes the following steps:
  • novel RNAi interference fragment and the pRNAT-LwCas13a-Neo after digestion
  • the vector is ligated to obtain a ligated product; wherein the sequence of the novel RNAi interference fragment is as shown in SEQ ID NO.1;
  • the novel RNAi interference fragment and RNAi vector provided by the invention can efficiently and specifically knock down the expression of the human INDO gene, and the application cost is low, which can promote the research of the function of the human INDO gene.
  • Figure 1 is a map of pRNAT-LwCas13a-Neo plasmid
  • Figure 2 shows the results of the INDO gene fluorescence quantitative PCR detection of experimental and control cells.
  • RNAi interference fragment targeting the human INDO gene was designed according to the crRNA design rules of Cas13a, and BamHI and AflII restriction sites were added to its 5 'and 3' ends, respectively, and its sequence is shown in SEQ ID NO.1.
  • pRNAT-LwCas13a-Neo plasmid (plasmid map shown in Figure 1) and the novel RNAi interfering fragment were digested with BamHI and AflII endonucleases respectively, and the target fragment was recovered by agarose gel electrophoresis and ligated with T4 DNA ligase Transformation of competent E. coli Stbl3 and sequencing.
  • the correct sequence is the new RNAi interference vector targeting the human INDO gene, which is named pRNAT-LwCas13a-INDO.
  • the correct strain was sequenced and identified in Example 1, and placed in an LB liquid medium having an ampicillin concentration of 100 ⁇ g / ml, and cultured with shaking at 250 rpm and 37 ° C. for 12-16 h. Collect the bacterial solution by centrifugation at 10,000 rpm at 4 ° C, discard the supernatant, collect the bacterial cells, and then extract the plasmid according to the instructions of the Endo-Free Plasmid Mini Kit kit to obtain the endotoxin-free pRNAT-LwCas13a-INDO vector.
  • the novel RNAi interference fragment and RNAi vector provided by the invention can efficiently and specifically knock down the expression of the human INDO gene, and the application cost is low, which can promote the research of the function of the human INDO gene.

Abstract

一种靶向人INDO基因的RNAi干扰片段、包含该RNAi的载体及其制备方法和其应用。该RNAi干扰片段如SEQ ID NO.1所示，可引导LwCas13a对人INDO基因转录形成的mRNA进行精准的识别与切割，实现对INDO基因的特异性表达干扰。

Description

一种靶向人INDO基因的新型RNAi干扰片段、RNAi载体及其制备方法和其应用 技术领域
本发明涉及生物技术领域，具体涉及一种靶向人INDO基因的新型RNAi干扰片段、RNAi载体及其制备方法和其应用。
 背景技术
免疫应答受多种因素影响和调节，从而维持机体内环境的稳定。巨噬细胞、树突状细胞等抗原提呈细胞表达的INDO清除局部微环境中的色氨酸，诱导T淋巴细胞的凋亡，通过调节性T细胞的作用抑制T细胞的克隆性增生，参于细胞免疫的调节；在机体维持正常的妊娠以及自身免疫性疾病、器官移植排斥反应、肿瘤等疾病的发生发展中起着重要作用。
 技术问题
INDO的活性可能是寻找防治免疫相关性疾病药物的新途径，需进行扎实的研究方可投入实际应用，但现有技术中虽然已有通过传统RNAi技术敲低INDO基因对其功能进行研究的报道，但由于这一技术特异性较差，潜在的脱靶风险较大，对相关研究的进展造成了一定的阻碍。
 技术解决方案
2016首次报道了一种RNA靶向的CRISPR酶——Cas13a。与CRISPR/Cas9切割DNA的活性不同，CRISPR/Cas13a能够用于切割细菌细胞中特定的RNA序列。研究表明，来自Leptotrichia wadei的LwCas13a能够以比现有RNAi工具更强的特异性在目标RNA上切割特定的位点。
有鉴于此，本发明提供一种靶向人INDO基因的新型RNAi干扰片段、RNAi载体及其制备方法和其应用，主要目的是提升针对INDO基因的RNAi特异性，减少或消除脱靶效应，促进INDO基因功能的研究。
为达到上述目的，本发明主要提供如下技术方案：
一种新型RNAi干扰片段，用于干扰人INDO基因，其序列如SEQ ID NO.1所示。
另一方面，一种新型RNAi干扰载体，用于干扰人INDO基因，所述新型RNAi干扰载体克隆携带新型RNAi干扰片段，所述新型RNAi干扰片段的序列如SEQ ID NO.1所示。
进一步地，所述新型RNAi干扰载体包括pRNAT-LwCas13a-Neo载体，所述pRNAT-LwCas13a-Neo载体与所述新型RNAi干扰片段连接。
一种新型RNAi干扰载体的制备方法，包括如下步骤 ：
a. 酶切pRNAT-LwCas13a-Neo载体，所述酶切位点为BamHI和AflII；
b. 将所述新型RNAi干扰片段与酶切后的所述pRNAT-LwCas13a-Neo 载体连接，得到连接产物；其中，所述新型RNAi干扰片段序列如SEQ ID NO.1所示；
c. 将所述连接产物转化至感受态大肠杆菌Stbl3中，筛选并将得到的菌液进行测序鉴定，并将测序结果与所述新型RNAi干扰片段序列完全一致的菌液进行扩增；
d. 从所述扩增的菌液中提取新型RNAi干扰载体。
 有益效果
本发明提供的一种靶向人INDO基因的新型RNAi干扰片段、RNAi载体可高效、特异地敲低人INDO基因的表达，而且应用成本低廉，可很好地推动人INDO基因功能的研究。
 附图说明
图1为pRNAT-LwCas13a-Neo质粒的图谱；
图2为实验组和对照组细胞的INDO基因荧光定量PCR检测结果。
 本发明的实施方式
为更进一步阐述本发明为达成预定发明目的所采用的技术手段及功效，结合较佳实施例详细说明如下。
实施例一
根据Cas13a的crRNA设计规则设计靶向人INDO基因的新型RNAi干扰片段，并在其5’端和3’端分别加上BamHI和AflII酶切位点，其序列如SEQ ID NO.1所示。
用BamHI和AflII内切酶分别对pRNAT-LwCas13a-Neo质粒（质粒图谱如图1所示）和所述新型RNAi干扰片段进行酶切，琼脂糖凝胶电泳回收目的片段并用T4 DNA连接酶进行连接、转化感受态大肠杆菌Stbl3及测序。测序正确的即为所述靶向人INDO基因的新型RNAi干扰载体，命名为pRNAT-LwCas13a-INDO。
实施例二
取实施例一中测序鉴定正确的菌株，置于氨苄青霉素浓度为100 μg/ml的LB液体培养基中，250 rpm、37℃振荡培养12-16 h。4℃，10000 rpm离心收集菌液，弃上清，收集菌体，然后按照Endo-Free Plasmid Mini Kit试剂盒说明书操作步骤提取质粒，得无内毒素的pRNAT-LwCas13a-INDO载体。
实施例三
培养Raji细胞，待Raji细胞的融合率达到50％～60％，接种后12～18h为最佳转染时间；转染前更换新鲜培养液，60 mm培养皿中加入3 ml培养基；转染时按照Lipofectamine 2000试剂盒说明书导入4μg的pRNAT-LwCas13a-INDO质粒，转染后48 h，加入800 μg/mL G418筛选10 d。筛选完成后，将嘌呤霉素的浓度降为200 μg/ml继续扩大培养细胞。。
实施例四
以未经任何处理的Raji细胞作为对照组，实施例三中筛选出的细胞为实验组，提取总RNA并进行逆转录后，荧光定量PCR检测INDO基因的表达水平，其结果如图2所示。可以看到，实验组细胞的INDO基因表达水平显著低于对照组细胞，说明所述靶向人INDO基因的新型RNAi干扰序列及载体可以实现对INDO基因的RNA干扰。
 工业实用性
本发明提供的一种靶向人INDO基因的新型RNAi干扰片段、RNAi载体可高效、特异地敲低人INDO基因的表达，而且应用成本低廉，可很好地推动人INDO基因功能的研究。

Claims (4)

  1. 一种新型RNAi干扰片段，用于干扰人INDO基因，其特征在于，所述RNAi干扰片段序列如SEQ ID NO.1所示。
  2. 一种新型RNAi干扰载体，用于干扰人INDO基因，其特征在于，所述新型RNAi干扰载体克隆携带新型RNAi干扰片段，所述新型RNAi干扰片段的序列如SEQ ID NO.1所示。
  3. 根据权利要求2所述的新型RNAi干扰载体，其特征在于，所述新型RNAi干扰载体包括pRNAT-LwCas13a-Neo载体，所述pRNAT-LwCas13a-Neo载体与所述新型RNAi干扰片段连接。
  4. 一种新型RNAi干扰载体的制备方法，其特征在于，包括如下步骤 ：
    a. 酶切pRNAT-LwCas13a-Neo载体，所述酶切位点为BamHI和AflII；
    b. 将所述新型RNAi干扰片段与酶切后的所述pRNAT-LwCas13a-Neo 载体连接，得到连接产物；其中，所述新型RNAi干扰片段序列如SEQ ID NO.1所示；
    c. 将所述连接产物转化至感受态大肠杆菌Stbl3中，筛选并将得到的菌液进行测序鉴定，并将测序结果与所述新型RNAi干扰片段序列完全一致的菌液进行扩增；
    d. 从所述扩增的菌液中提取新型RNAi干扰载体。
PCT/CN2018/093863 2018-06-29 2018-06-29 一种靶向人 INDO 基因的新型 RNAi 干扰片段、 RNAi 载体及其制备方法和其应用 WO2020000453A1 (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CN2018/093863 WO2020000453A1 (zh) 2018-06-29 2018-06-29 一种靶向人 INDO 基因的新型 RNAi 干扰片段、 RNAi 载体及其制备方法和其应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2018/093863 WO2020000453A1 (zh) 2018-06-29 2018-06-29 一种靶向人 INDO 基因的新型 RNAi 干扰片段、 RNAi 载体及其制备方法和其应用

Publications (1)

Publication Number Publication Date
WO2020000453A1 true WO2020000453A1 (zh) 2020-01-02

Family

ID=68985318

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2018/093863 WO2020000453A1 (zh) 2018-06-29 2018-06-29 一种靶向人 INDO 基因的新型 RNAi 干扰片段、 RNAi 载体及其制备方法和其应用

Country Status (1)

Country Link
WO (1) WO2020000453A1 (zh)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101040042A (zh) * 2004-08-16 2007-09-19 细胞研究私人有限公司 自脐带羊膜分离干/祖细胞
CN101235372A (zh) * 2008-02-29 2008-08-06 苏先狮 一种抗HBV核心区的siRNA表达模板和应用
CN101392284A (zh) * 2008-11-06 2009-03-25 长春康彼达科技有限公司 一种抗癌天然药物筛选模型的建立及应用
CN101835890A (zh) * 2008-06-27 2010-09-15 国立大学法人京都大学 有效建立诱导的多能干细胞的方法
CN104531760A (zh) * 2014-12-26 2015-04-22 中南大学 Dp71蛋白的短发夹RNA干扰质粒及其应用方法
CN107557455A (zh) * 2017-09-15 2018-01-09 国家纳米科学中心 一种基于CRISPR‑Cas13a的特异性核酸片段的检测方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101040042A (zh) * 2004-08-16 2007-09-19 细胞研究私人有限公司 自脐带羊膜分离干/祖细胞
CN101235372A (zh) * 2008-02-29 2008-08-06 苏先狮 一种抗HBV核心区的siRNA表达模板和应用
CN101835890A (zh) * 2008-06-27 2010-09-15 国立大学法人京都大学 有效建立诱导的多能干细胞的方法
CN101392284A (zh) * 2008-11-06 2009-03-25 长春康彼达科技有限公司 一种抗癌天然药物筛选模型的建立及应用
CN104531760A (zh) * 2014-12-26 2015-04-22 中南大学 Dp71蛋白的短发夹RNA干扰质粒及其应用方法
CN107557455A (zh) * 2017-09-15 2018-01-09 国家纳米科学中心 一种基于CRISPR‑Cas13a的特异性核酸片段的检测方法

Similar Documents

Publication Publication Date Title
CN107502608B (zh) 用于敲除人ALDH2基因的sgRNA、ALDH2基因缺失细胞株的构建方法及应用
CN107828738A (zh) 一种dna甲基转移酶缺陷型cho细胞系及其制备方法及应用
CN108315330A (zh) CRISPR-Cas9系统特异性靶向人RSPO2基因的sgRNA及敲除方法和应用
EP3394246A1 (en) Methods for extending the replicative capacity of somatic cells during an ex vivo cultivation process
CN110484538A (zh) 识别猪ROSA26基因的sgRNA及其编码DNA、基因编辑方法、试剂盒和应用
CN109517820A (zh) 一种靶向HPK1的gRNA以及HPK1基因编辑方法
US11866703B2 (en) Method for knocking out N-myristoyltransferase (NMT) gene from Eimeria tenella
CN107501405A (zh) 一种细胞自噬抑制多肽
CN111607594A (zh) 一种基于CRISPR-Cas9编辑技术的敲除猪IRF8基因的细胞系及其构建方法
EP1930423A1 (en) Expression vector, transformant having the expression vector introduced therein, and process for production of heterologous protein
CN103864914A (zh) 高纯度白细胞介素-24包涵体的制备方法
CN109369795B (zh) 一种调控巨噬细胞免疫功能活性的蛋白质及其应用
CN109609551A (zh) 一种利用CRISPR/Cas9+AAV制备通用型CAR-T细胞的方法
CN104745551A (zh) 利用talen敲除人乳头瘤病毒e6e7癌基因的方法
CN116218846B (zh) 一种调控猪Ptrf基因表达的增强子序列的鉴定及其应用
CN106620703A (zh) Gins2基因或蛋白的抑制剂在制备抗肿瘤药物中的应用
CN112190712A (zh) 氢巯基氧化酶1激动剂和索拉菲尼联合在制备治疗肝癌细胞中的应用
CN109453366B (zh) 一种抗肿瘤蛋白质的制备方法及用途
WO2020000453A1 (zh) 一种靶向人 INDO 基因的新型 RNAi 干扰片段、 RNAi 载体及其制备方法和其应用
EA010924B1 (ru) Способ получения партий рекомбинантного аденовируса и используемые для этого пакующие клетки
CN110229816B (zh) 用于敲除RBP4基因的sgRNA、RBP4基因缺失细胞株的构建方法及应用
CN110893240B (zh) Nme2基因在抑制禽呼肠病毒复制中的应用
CN109182341B (zh) 一种抗肿瘤蛋白质及其应用
WO2020000450A1 (zh) 靶向人CD272基因的新型RNAi干扰片段、RNAi载体及其制备方法和其应用
CN103014023B (zh) 一个簇毛麦金属转运蛋白基因及其所编码的蛋白质和应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18924369

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18924369

Country of ref document: EP

Kind code of ref document: A1